Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allo SCT From HLA Haploidentical Related Donors Using Sub-Myeloablative Conditioning For Patients With High Risk Hemoglobinopathies: Hemo SS, Hemo SC, Hemo SB0/+ Thalassemia, Homozygous B0/+ Thalassemia or Severe B0/+ Thalassemia Variants

NCT00040417 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00040417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00040417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allo SCT From HLA Haploidentical Related Donors Using Sub-Myeloablative Conditioning For Patients With High Risk Hemoglobinopathies: Hemo SS, Hemo SC, Hemo SB0/+ Thalassemia, Homozygous B0/+ Thalassemia or Severe B0/+ Thalassemia Variants
Lead sponsor
Baylor College of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2000
Completion date
November 21, 2003
Enrollment
15
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemoglobinopathy, sickle cell anemia, thalassemia